Multicenter evaluation of arsenic trioxide dosing in obese patients with low-intermediate risk acute promyelocytic leukemia

Leuk Lymphoma. 2019 Dec;60(14):3557-3560. doi: 10.1080/10428194.2019.1639163. Epub 2019 Jul 11.

Authors

Erin Hickey¹, Bryant Clemons¹, Shawn Griffin², Jessica Cox¹, Stephanie Sutphin¹, Reshma Ramlal³, Lydia Benitez¹

Affiliations

¹ Department of Pharmacy, University of Kentucky HealthCare, Lexington, KY, USA.
² Department of Pharmacy, Indiana University Health, Indianapolis, IN, USA.
³ University of Kentucky Markey Cancer Center, Lexington, KY, USA.

PMID: 31294640
DOI: 10.1080/10428194.2019.1639163

No abstract available

Publication types

Letter
Multicenter Study

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects*
Arsenic Trioxide / administration & dosage
Arsenic Trioxide / adverse effects*
Female
Follow-Up Studies
Humans
Leukemia, Promyelocytic, Acute / drug therapy*
Leukemia, Promyelocytic, Acute / pathology
Long QT Syndrome / chemically induced*
Long QT Syndrome / pathology
Male
Middle Aged
Obesity / physiopathology*
Prognosis
Retrospective Studies
Young Adult

Substances

Antineoplastic Agents
Arsenic Trioxide